Le Nghiem Quan, Tran Thy Van, Minh Tran Tam Thi, Kieu Dang Nga Thi, Truong Quoc Ky, Vo Trung Quang
Department of Pharmacy Industry, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
Department of Pharmacy Administration, Faculty of Pharmacy, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
J Pak Med Assoc. 2019 Jun;69(Suppl 2)(6):S2-S9.
To estimate the economic burden of asthma treatment by quantifying direct medical expenditures at one of Southern Vietnam's public hospitals base on the hospital perspective.
A retrospective, prevalence-based, cost-of-illness analysis was developed using the hospital's electronic medical record data to calculate the economic burden of asthma (ICD-10 code J45, J46) through direct medical costs from January 2014 to December 2017. All costs were converted to US dollars and to the year 2018. Data were analyzed using descriptive statistics. The potential correlations between variables were evaluated using the chisquare test and bootstrap difference.
The average direct medical cost of asthma was estimated to range from $34.7 to $55.3 per - outpatient and $45.1 to $107.2 per - inpatient annually. The total economic burdens for 4 years from 2014 to 2017 were $110,387.4 from outpatients and $13,413.8 from inpatients. The most influential component was medication cost.
Asthma places a high economic burden on individuals and the healthcare system in Vietnam. The findings of this study provide health administrators with important evidence to enhance surveillance of the disease and to allow suitable drafting of national health policy.
从医院角度，通过量化越南南部一家公立医院的直接医疗支出，估算哮喘治疗的经济负担。
利用医院电子病历数据开展一项基于患病率的回顾性疾病成本分析，通过2014年1月至2017年12月的直接医疗成本计算哮喘（国际疾病分类第十版编码J45、J46）的经济负担。所有成本均换算为美元并折算至2018年。采用描述性统计方法分析数据。使用卡方检验和自抽样差异评估变量之间的潜在相关性。
哮喘患者门诊平均每年直接医疗成本估计为34.7美元至55.3美元，住院患者平均每年为45.1美元至107.2美元。2014年至2017年4年的总经济负担，门诊患者为110387.4美元，住院患者为13413.8美元。最具影响力的组成部分是药品成本。
哮喘给越南的个人和医疗系统带来了沉重的经济负担。本研究结果为卫生管理人员提供了重要证据，以加强对该疾病的监测，并有助于合理制定国家卫生政策。
